Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
UNKNOWN
Clinical Phase
PHASE2/PHASE3
Total Enrollment
903 participants
Study Classification
INTERVENTIONAL
Study Start Date
2016-02-29
Study Completion Date
2018-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The aim of this study is to establish the influence of early administration of a bolus of intravascular fluid in patients with a diagnosis of acute pancreatitis on the course and outcome of disease.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Aggressive Fluid Hydration for the Prevention of Post-ERCP Pancreatitis
NCT02821546
Pancreatitis
COMPLETED
PHASE3
Balanced Crystalloid Solutions for Acute Pancreatitis
NCT04688645
Acute Pancreatitis
UNKNOWN
PHASE4
Goal-directed Fluid Resuscitation in Acute Pancreatitis
NCT00853515
Acute Pancreatitis
TERMINATED
NA
Moderate Versus Aggressive Fluids for Acute Pancreatitis
NCT01761539
Pancreatitis
COMPLETED
NA
High Volume Lactated Ringer's Solution and Pancreatitis
NCT02050048
Pancreatitis
TERMINATED
PHASE2/PHASE3
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This is a prospective, randomized, controlled clinical trial of standard versus enhanced hydration in patients diagnosed with acute pancreatitis within the first hour of diagnosis.
Patients admitted in the Emergency Department with the clinical suspicion of acute pancreatitis will be processed through the history, physical examination and laboratory findings. The diagnosis of acute pancreatitis is established by the presence of 2 of the 3 following criteria: typical abdominal pain, serum amylase and / or lipase greater than three times the upper limit of normal, and characteristic findings from abdominal imaging. Patients will be informed about the study protocol and the possible risks and adverse events, after which they will be asked to accept participation in the study. Acceptance of participation will be confirmed by signed informed consent.
After acceptance patients will be randomized by computer-generated sequences of random numbers in the two groups Group one (1) will receive a bolus of fluid 20 ml / kg of Ringer's solution for infusion within one hour of the diagnosis and the group two (2) will receive a bolus of fluid 40 ml / kg of Ringer's solution for infusion within one hour of the diagnosis. All patients who have the diagnosis of acute pancreatitis, but did not agree to participate in research or have some other exclusion criteria will be treated according to the standards of good clinical practice and the recommendations of the current clinical guidelines for the treatment of acute pancreatitis. Exclusion criteria beside refusal to sign informed consent are: age less than 18 years, pregnancy, patients with physical signs of heart failure, previously known congestive heart failure (NYHA III - IV) and severe kidney disease more than one month before the diagnosis of acute pancreatitis (defined as severe reduction in eGFR less than 30 ml/min/1.73 m2). Patients who develop acute renal failure as a result of acute pancreatitis will be involved in research .
Given the importance of early hydration in patients with acute pancreatitis and the lack of clearly defined dose of administered fluid in the current literature, aim of this study was to determine the influence of the size of the dose bolus of intravascular fluid after the diagnosis of acute pancreatitis in the further course and outcome of disease.
The study will be conducted in the Emergency Department, Clinical Hospital Centre, Rijeka.
Patients admitted in the Emergency Department with the clinical suspicion of acute pancreatitis will be processed through the history, physical examination and laboratory findings. The diagnosis of acute pancreatitis is established by the presence of 2 of the 3 following criteria: typical abdominal pain, serum amylase and / or lipase greater than three times the upper limit of normal, and characteristic findings from abdominal imaging. Patients will be informed about the study protocol and the possible risks and adverse events, after which they will be asked to accept participation in the study. Acceptance of participation will be confirmed by signed informed consent.
After acceptance patients will be randomized by computer-generated sequences of random numbers in the two groups Group one (1) will receive a bolus of fluid 20 ml / kg of Ringer's solution for infusion within one hour of the diagnosis and the group two (2) will receive a bolus of fluid 40 ml / kg of Ringer's solution for infusion within one hour of the diagnosis. All patients who have the diagnosis of acute pancreatitis, but did not agree to participate in research or have some other exclusion criteria will be treated according to the standards of good clinical practice and the recommendations of the current clinical guidelines for the treatment of acute pancreatitis. Exclusion criteria beside refusal to sign informed consent are: age less than 18 years, pregnancy, patients with physical signs of heart failure, previously known congestive heart failure (NYHA III - IV) and severe kidney disease more than one month before the diagnosis of acute pancreatitis (defined as severe reduction in eGFR less than 30 ml/min/1.73 m2). Patients who develop acute renal failure as a result of acute pancreatitis will be involved in research .
Given the importance of early hydration in patients with acute pancreatitis and the lack of clearly defined dose of administered fluid in the current literature, aim of this study was to determine the influence of the size of the dose bolus of intravascular fluid after the diagnosis of acute pancreatitis in the further course and outcome of disease.
The study will be conducted in the Emergency Department, Clinical Hospital Centre, Rijeka.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Pancreatitis
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Ringer lactate 20 mL/kg
This group of subjects will receive a bolus of 20 ml / kg of Ringer's solution for infusion within first hour of the diagnosis
Group Type
EXPERIMENTAL
Ringer lactate
Intervention Type
DRUG
Ringer lactate 40 ml/kg
This group of subjects will receive a bolus of 40 ml / kg of Ringer's solution for infusion within first hour of the diagnosis
Group Type
EXPERIMENTAL
Ringer lactate
Intervention Type
DRUG
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ringer lactate
Intervention Type
DRUG
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
All patients with diagnosis of acute pancreatitis.
Exclusion Criteria
1. Refusal to sign informed consent
2. Age less than 18 years
3. Pregnancy
4. Patients with physical signs of heart failure,
5. Previously known congestive heart failure ( NYHA III - IV )
6. Severe kidney disease more than one month before the diagnosis of acute pancreatitis (defined as severe reduction in eGFR less than 30 ml/min/1.73 m2) . Patients who develop acute renal failure as a result of acute pancreatitis will be involved in research .
2. Age less than 18 years
3. Pregnancy
4. Patients with physical signs of heart failure,
5. Previously known congestive heart failure ( NYHA III - IV )
6. Severe kidney disease more than one month before the diagnosis of acute pancreatitis (defined as severe reduction in eGFR less than 30 ml/min/1.73 m2) . Patients who develop acute renal failure as a result of acute pancreatitis will be involved in research .
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital Rijeka
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Vanja Giljaca
M.D. PhD
Responsibility Role
PRINCIPAL_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Vanja Giljača, M.D. PhD
Role: STUDY_CHAIR
University Hospital Rijeka
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
UHRijeka
Rijeka, Rijeka, Croatia
Site Status
RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
Croatia
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Dugernier T, Starkel P, Laterre PF, Reynaert MS. Severe acute pancreatitis: pathophysiologic mechanisms underlying pancreatic necrosis and remote organ damage. Acta Gastroenterol Belg. 1996 Jul-Sep;59(3):178-85.
Reference Type
BACKGROUND
Cuthbertson CM, Christophi C. Disturbances of the microcirculation in acute pancreatitis. Br J Surg. 2006 May;93(5):518-30. doi: 10.1002/bjs.5316.
Reference Type
BACKGROUND
Zhao G, Zhang JG, Wu HS, Tao J, Qin Q, Deng SC, Liu Y, Liu L, Wang B, Tian K, Li X, Zhu S, Wang CY. Effects of different resuscitation fluid on severe acute pancreatitis. World J Gastroenterol. 2013 Apr 7;19(13):2044-52. doi: 10.3748/wjg.v19.i13.2044.
Reference Type
BACKGROUND
Tenner S, Baillie J, DeWitt J, Vege SS; American College of Gastroenterology. American College of Gastroenterology guideline: management of acute pancreatitis. Am J Gastroenterol. 2013 Sep;108(9):1400-15; 1416. doi: 10.1038/ajg.2013.218. Epub 2013 Jul 30.
Reference Type
BACKGROUND
Bradley EL 3rd. A clinically based classification system for acute pancreatitis. Summary of the International Symposium on Acute Pancreatitis, Atlanta, Ga, September 11 through 13, 1992. Arch Surg. 1993 May;128(5):586-90. doi: 10.1001/archsurg.1993.01420170122019.
Reference Type
BACKGROUND
Vege SS, Chari ST. Organ failure as an indicator of severity of acute pancreatitis: time to revisit the Atlanta classification. Gastroenterology. 2005 Apr;128(4):1133-5. doi: 10.1053/j.gastro.2005.02.059. No abstract available.
Reference Type
BACKGROUND
Thoeni RF. The revised Atlanta classification of acute pancreatitis: its importance for the radiologist and its effect on treatment. Radiology. 2012 Mar;262(3):751-64. doi: 10.1148/radiol.11110947.
Reference Type
BACKGROUND
Vege SS, Gardner TB, Chari ST, Munukuti P, Pearson RK, Clain JE, Petersen BT, Baron TH, Farnell MB, Sarr MG. Low mortality and high morbidity in severe acute pancreatitis without organ failure: a case for revising the Atlanta classification to include "moderately severe acute pancreatitis". Am J Gastroenterol. 2009 Mar;104(3):710-5. doi: 10.1038/ajg.2008.77. Epub 2009 Feb 3.
Reference Type
BACKGROUND
Petrov MS, Windsor JA. Classification of the severity of acute pancreatitis: how many categories make sense? Am J Gastroenterol. 2010 Jan;105(1):74-6. doi: 10.1038/ajg.2009.597. Epub 2009 Oct 20.
Reference Type
BACKGROUND
Banks PA, Bollen TL, Dervenis C, Gooszen HG, Johnson CD, Sarr MG, Tsiotos GG, Vege SS; Acute Pancreatitis Classification Working Group. Classification of acute pancreatitis--2012: revision of the Atlanta classification and definitions by international consensus. Gut. 2013 Jan;62(1):102-11. doi: 10.1136/gutjnl-2012-302779. Epub 2012 Oct 25.
Reference Type
BACKGROUND
Ranson JH, Rifkind KM, Roses DF, Fink SD, Eng K, Spencer FC. Prognostic signs and the role of operative management in acute pancreatitis. Surg Gynecol Obstet. 1974 Jul;139(1):69-81. No abstract available.
Reference Type
BACKGROUND
Blamey SL, Imrie CW, O'Neill J, Gilmour WH, Carter DC. Prognostic factors in acute pancreatitis. Gut. 1984 Dec;25(12):1340-6. doi: 10.1136/gut.25.12.1340.
Reference Type
BACKGROUND
Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med. 1985 Oct;13(10):818-29.
Reference Type
BACKGROUND
Singh VK, Wu BU, Bollen TL, Repas K, Maurer R, Johannes RS, Mortele KJ, Conwell DL, Banks PA. A prospective evaluation of the bedside index for severity in acute pancreatitis score in assessing mortality and intermediate markers of severity in acute pancreatitis. Am J Gastroenterol. 2009 Apr;104(4):966-71. doi: 10.1038/ajg.2009.28. Epub 2009 Mar 17.
Reference Type
BACKGROUND
Balthazar EJ. Staging of acute pancreatitis. Radiol Clin North Am. 2002 Dec;40(6):1199-209. doi: 10.1016/s0033-8389(02)00047-7.
Reference Type
BACKGROUND
Juneja D, Gopal PB, Ravula M. Scoring systems in acute pancreatitis: which one to use in intensive care units? J Crit Care. 2010 Jun;25(2):358.e9-358.e15. doi: 10.1016/j.jcrc.2009.12.010. Epub 2010 Feb 10.
Reference Type
BACKGROUND
Schutte K, Malfertheiner P. Markers for predicting severity and progression of acute pancreatitis. Best Pract Res Clin Gastroenterol. 2008;22(1):75-90. doi: 10.1016/j.bpg.2007.10.013.
Reference Type
BACKGROUND
Wu BU, Johannes RS, Sun X, Tabak Y, Conwell DL, Banks PA. The early prediction of mortality in acute pancreatitis: a large population-based study. Gut. 2008 Dec;57(12):1698-703. doi: 10.1136/gut.2008.152702. Epub 2008 Jun 2.
Reference Type
BACKGROUND
International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) adopts Consolidated Guideline on Good Clinical Practice in the Conduct of Clinical Trials on Medicinal Products for Human Use. Int Dig Health Legis. 1997;48(2):231-4. No abstract available.
Reference Type
BACKGROUND
Haydock MD, Mittal A, van den Heever M, Rossaak JI, Connor S, Rodgers M, Petrov MS, Windsor JA; Pancreas Network of New Zealand. National survey of fluid therapy in acute pancreatitis: current practice lacks a sound evidence base. World J Surg. 2013 Oct;37(10):2428-35. doi: 10.1007/s00268-013-2105-7.
Reference Type
BACKGROUND
Khajavi MR, Etezadi F, Moharari RS, Imani F, Meysamie AP, Khashayar P, Najafi A. Effects of normal saline vs. lactated ringer's during renal transplantation. Ren Fail. 2008;30(5):535-9. doi: 10.1080/08860220802064770.
Reference Type
BACKGROUND
Wu BU, Hwang JQ, Gardner TH, Repas K, Delee R, Yu S, Smith B, Banks PA, Conwell DL. Lactated Ringer's solution reduces systemic inflammation compared with saline in patients with acute pancreatitis. Clin Gastroenterol Hepatol. 2011 Aug;9(8):710-717.e1. doi: 10.1016/j.cgh.2011.04.026. Epub 2011 May 12.
Reference Type
BACKGROUND
Nasr JY, Papachristou GI. Early fluid resuscitation in acute pancreatitis: a lot more than just fluids. Clin Gastroenterol Hepatol. 2011 Aug;9(8):633-4. doi: 10.1016/j.cgh.2011.03.010. Epub 2011 Mar 21. No abstract available.
Reference Type
BACKGROUND
Warndorf MG, Kurtzman JT, Bartel MJ, Cox M, Mackenzie T, Robinson S, Burchard PR, Gordon SR, Gardner TB. Early fluid resuscitation reduces morbidity among patients with acute pancreatitis. Clin Gastroenterol Hepatol. 2011 Aug;9(8):705-9. doi: 10.1016/j.cgh.2011.03.032. Epub 2011 Apr 8.
Reference Type
BACKGROUND
Wall I, Badalov N, Baradarian R, Iswara K, Li JJ, Tenner S. Decreased mortality in acute pancreatitis related to early aggressive hydration. Pancreas. 2011 May;40(4):547-50. doi: 10.1097/MPA.0b013e318215368d.
Reference Type
BACKGROUND
Stimac D, Poropat G. Rational therapy of acute pancreatitis. Dig Dis. 2010;28(2):310-6. doi: 10.1159/000319406. Epub 2010 Sep 1.
Reference Type
BACKGROUND
Tenner S. Initial management of acute pancreatitis: critical issues during the first 72 hours. Am J Gastroenterol. 2004 Dec;99(12):2489-94. doi: 10.1111/j.1572-0241.2004.40329.x.
Reference Type
BACKGROUND
Aggarwal A, Manrai M, Kochhar R. Fluid resuscitation in acute pancreatitis. World J Gastroenterol. 2014 Dec 28;20(48):18092-103. doi: 10.3748/wjg.v20.i48.18092.
Reference Type
BACKGROUND
ARDS Definition Task Force; Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND, Caldwell E, Fan E, Camporota L, Slutsky AS. Acute respiratory distress syndrome: the Berlin Definition. JAMA. 2012 Jun 20;307(23):2526-33. doi: 10.1001/jama.2012.5669.
Reference Type
BACKGROUND
Werner J, Hartwig W, Uhl W, Muller C, Buchler MW. Useful markers for predicting severity and monitoring progression of acute pancreatitis. Pancreatology. 2003;3(2):115-27. doi: 10.1159/000070079.
Reference Type
BACKGROUND
Isenmann R, Runzi M, Kron M, Kahl S, Kraus D, Jung N, Maier L, Malfertheiner P, Goebell H, Beger HG; German Antibiotics in Severe Acute Pancreatitis Study Group. Prophylactic antibiotic treatment in patients with predicted severe acute pancreatitis: a placebo-controlled, double-blind trial. Gastroenterology. 2004 Apr;126(4):997-1004. doi: 10.1053/j.gastro.2003.12.050.
Reference Type
BACKGROUND
Banks PA, Freeman ML; Practice Parameters Committee of the American College of Gastroenterology. Practice guidelines in acute pancreatitis. Am J Gastroenterol. 2006 Oct;101(10):2379-400. doi: 10.1111/j.1572-0241.2006.00856.x. No abstract available.
Reference Type
BACKGROUND
Khan AA, Parekh D, Cho Y, Ruiz R, Selby RR, Jabbour N, Genyk YS, Mateo R. Improved prediction of outcome in patients with severe acute pancreatitis by the APACHE II score at 48 hours after hospital admission compared with the APACHE II score at admission. Acute Physiology and Chronic Health Evaluation. Arch Surg. 2002 Oct;137(10):1136-40. doi: 10.1001/archsurg.137.10.1136.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AP01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Lactated Ringer's Versus Normal Saline for Acute Pancreatitis
NCT03642769
COMPLETED
NA
Comparing the Effects of Lactated Ringers and Normal Saline in Acute Pancreatitis
NCT03242473
COMPLETED
NA
Dextran 40 Plus Ringer's Lactate Vs. Ringer's Lactate Alone for Fluid Resuscitation in Acute Pancreatitis
NCT06835023
RECRUITING
NA
Aggressive Versus Non-aggressive Goal-directed Fluid Resuscitation in Acute Pancreatitis
NCT04381169
TERMINATED
PHASE3
Aggressive Intravenous Hydration With Lactated Ringer's Solution for Prevention of Post-ESWL Pancreatitis
NCT05772234
COMPLETED
NA
Normal Saline Versus Lactated Ringer's Solution for Acute Pancreatitis Resuscitation
NCT05781243
COMPLETED
PHASE4
Effects of Restrictive Fluid Strategy on Postoperative Oliguric Pancreatic Surgery Patients
NCT03553394
TERMINATED
NA
The Use of a Restrictive Fluid Regimen With Hypertonic Saline for Patients Undergoing Pancreaticoduodenectomy
NCT01428050
UNKNOWN
PHASE2
Bicarbonated Ringer's Solution Versus Lactated Ringer's Solution in Patients With Septic Shock
NCT04449757
UNKNOWN
NA
Effect of Human Plasma Protein Transfusion With and Without Crystalloids During Major Liver Resection Surgeries
NCT05033704
UNKNOWN
NA
Kinetics of Surfactant Proteins, Phosphatidylcholine and Body Water in Intensive Care Unit (ICU)
NCT03371680
COMPLETED
NA
Randomized Trial of Restrictive Versus Liberal Perioperative Fluid Management for Patients Undergoing Pancreatic Resection
NCT01058746
COMPLETED
NA
Application of Sodium Bicarbonate Ringer's Solution in Laparoscopic Hepatectomy
NCT05830136
RECRUITING
NA
Continuous Passive Paracentesis for Intra-abdominal Hypertension
NCT04322201
UNKNOWN
NA
Comparison Between Hyperoncotic and Isooncotic Albumin to Support Blood Loss Replacement
NCT05391607
COMPLETED
PHASE4
Midodrine Versus Albumin for Prevention of Paracentesis Induced Circulatory Disturbance
NCT05240391
COMPLETED
PHASE3
Volume Resuscitation in Cirrhosis With Sepsis Induced Hypotension
NCT05059795
COMPLETED
Fluid Collections Management in Severe Acute Pancreatitis
NCT01321060
UNKNOWN
NA
Extension of the RUSH Protocol for Volume Responsiveness
NCT03285269
WITHDRAWN
Comparison And Outcomes Of Fluid Resucitation With 0.9% Normal Saline And 5% Albumin In Cirrhosis Patients With Sepsis Induced Hypotension
NCT02462902
COMPLETED
NA
Comparison of Colloid (20% Albumin) Versus Crystalloid (Plasmalyte) for Fluid Resuscitation in Cirrhotics With Sepsis Induced Hypotension.
NCT02721238
COMPLETED
NA
Mini Bolus for Fluid Challenge Responsiveness in the Emergency Department
NCT05369559
RECRUITING
EARLY_PHASE1
Use of a Mini-fluid Bolus to Identify Fluid Responsiveness
NCT03058653
WITHDRAWN
NA
Clinical Effects of Ringers Lactate Versus Sterofundin/ Plasmalyte Solution in Patients With Sepsis
NCT07239713
RECRUITING
NA
Fluid Responsiveness Prediction at the Bedside
NCT00721604
COMPLETED